✦ LIBER ✦

Phase I and pharmacologic study of diflomotecan (BN80915) administered intravenously daily for 5 consecutive days every 3 weeks in patients with solid tumors

Book ID: 117659481
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 144 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)80789-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1 and pharmacokinetic study of T

A phase 1 and pharmacokinetic study of TAS-106 administered weekly for 3 consecutive weeks every 28 days in patients with solid tumors

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Final results of a phase I and pharmacok

Final results of a phase I and pharmacokinetic study of γ-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors

✍ Mary Johansen; Thomas Zukowski; PauloM. Hoff; RobertA. Newman; Dan Ni; Toni Hutt 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 226 KB

Phase I dose-escalation study of vinflun

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors

✍ Calvo, E.; Vermorken, J. B.; Hiret, S.; Rodon, J.; Cortes, J.; Senellart, H.; de 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 242 KB

A Phase II study of intravenous exatecan

A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma

✍ Francisco J. Esteva; Edgardo Rivera; Massimo Cristofanilli; Vicente Valero; Mela 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract ## BACKGROUND The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline‐resistant and taxane‐resistant, metastatic breast carcinoma. ## METHODS All patients had clinical evi

Phase I study of cisplatin, irinotecan,

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours

✍ Chen, X; Oza, A M; Kusenda, Z; Yi, Q-L; Kochman, D; Moore, M J; Davis, A J; Siu, 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 127 KB

A phase I study of ifosfamide with mesna

A phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors

✍ Charles B. Pratt; William H. Meyer; Edwin C. Douglass; Laura Bowman; Judith Wili 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views